GSK press releases
Follow
ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
Results build on LATITUDE study and robust body of evidence supporting investigational use.
